Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial | Zendy

Menter Thomas | Zendy; Hayoz Stefanie | Zendy; Zucca Emanuele | Zendy; Kimby Eva | Zendy; Dirnhofer Stefan | Zendy; Tzankov Alexandar | Zendy

Premium

Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial

Author(s) -

Menter Thomas,

Hayoz Stefanie,

Zucca Emanuele,

Kimby Eva,

Dirnhofer Stefan,

Tzankov Alexandar

Publication year - 2020

Publication title -

british journal of haematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.907

H-Index - 186

eISSN - 1365-2141

pISSN - 0007-1048

DOI - 10.1111/bjh.16876

Subject(s) - germinal center , cytotoxic t cell , follicular lymphoma , tumor microenvironment , cd8 , medicine , cancer research , rituximab , lymphoma , cd20 , immunology , gata3 , biology , oncology , b cell , immune system , antibody , in vitro , transcription factor , gene , biochemistry

(shown in Fig 1). Fig S3. Receiver operating characteristic (ROC) curves of Matutes score calculated using either A) FMC7% (area under the curve [AUC] 0.9994, 95% CI 0.999–1), B) CD20 MFI (AUC 0.9995, 95% CI = 0.999–1), or C) without FMC7 (AUC 0.996, 95% CI 0.993–0.999). For a threshold of 4 (A and B), sensitivity for the diagnosis of CLL was 100% (95% CI 98.4– 100) and 100% (95% CI 98.5–100) for A and B, respectively. Specificity was 97.1% (95% CI 94.3–98.7) and 98.1% (95% CI 95.7–99.3) for A and B, respectively. For a threshold of 3 (C), sensitivity for the diagnosis of CLL was 97.6% (95% CI 94.8–99.1) and specificity 98.9% (95% CI 96.9–99.8).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research